AbbVie(ABBV) - 2025 Q3 - Quarterly Results

FORM 8-K Filing Information This section provides administrative details for the Form 8-K filing, including registrant identification and event date Registrant and Filing Details This section provides basic identification details for the Form 8-K filing, including the registrant's name, address, and the date of the earliest event reported - Registrant is ABBVIE INC., located at 1 North Waukegan Road, North Chicago, Illinois[1][2] - The date of the earliest event reported is October 3, 2025[1] Securities Registered This section lists the classes of securities registered by AbbVie Inc. pursuant to Section 12(b) of the Act, including common stock and various senior notes, along with their trading symbols and the exchanges on which they are registered Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.01 Par Value | ABBV | New York Stock Exchange, NYSE Texas | | 0.750% Senior Notes due 2027 | ABBV27 | New York Stock Exchange | | 2.125% Senior Notes due 2028 | ABBV28 | New York Stock Exchange | | 2.625% Senior Notes due 2028 | ABBV28B | New York Stock Exchange | | 2.125% Senior Notes due 2029 | ABBV29 | New York Stock Exchange | | 1.250% Senior Notes due 2031 | ABBV31 | New York Stock Exchange | Item 2.02 Results of Operations and Financial Condition This section outlines AbbVie's preliminary financial estimates for Q3 2025, highlighting a significant pre-tax acquired IPR&D and milestones expense Third Quarter 2025 Preliminary Financial Estimates AbbVie expects its Q3 2025 GAAP and adjusted non-GAAP earnings to be significantly impacted by a $2.7 billion pre-tax acquired IPR&D and milestones expense, resulting in an unfavorable $1.50 impact per share - Q3 2025 GAAP and adjusted non-GAAP earnings are expected to include $2.7 billion pre-tax acquired IPR&D and milestones expense[5] - This expense represents an unfavorable impact of $1.50 to both GAAP and adjusted non-GAAP diluted earnings per share[5] - Results for the quarter ended September 30, 2025, are preliminary and subject to financial statement closing procedures[5] Updated Earnings Per Share Guidance The company has updated its full-year and third-quarter 2025 adjusted diluted EPS guidance to include the impact of the acquired IPR&D and milestones expense, which was previously excluded from forecasts due to its uncertain nature - AbbVie does not typically forecast acquired IPR&D and milestones expense due to uncertainty in occurrence and timing[6] Updated Adjusted Diluted EPS Guidance (including Q3 2025 IPR&D expense) | Period | Adjusted Diluted EPS Guidance Range | | :----- | :---------------------------------- | | Full-year 2025 | $10.38 - $10.58 | | Third Quarter 2025 | $1.74 - $1.78 | - Guidance for 2025, including the estimated acquired IPR&D and milestones expense, is furnished as Exhibit 99.1[7] Forward-Looking Statements This section provides a disclaimer regarding the inherent risks and uncertainties associated with forward-looking statements in the report Disclaimer on Future Performance This standard disclosure warns that some statements in the report are forward-looking and subject to various risks and uncertainties, including intellectual property challenges, competition, R&D difficulties, litigation, regulatory changes, and macroeconomic factors, which could cause actual results to differ materially - Forward-looking statements are identified by words like 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions[9] - Such statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied[9] - Risks include challenges to intellectual property, competition, R&D difficulties, adverse litigation, regulatory changes, and global macroeconomic factors[9] Item 9.01 Financial Statements and Exhibits This section lists the financial statements and exhibits included in the Form 8-K filing Exhibits Filed This item lists the exhibits accompanying the Form 8-K, specifically Exhibit 99.1, which provides detailed guidance including the impact of acquired IPR&D and milestones expense, and Exhibit 104 for the Inline XBRL cover page Exhibits | Exhibit No. | Exhibit Description | | :---------- | :------------------ | | 99.1 | Guidance including the impact of acquired IPR&D and milestones expense | | 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) | SIGNATURE This section formally concludes the Form 8-K filing, indicating due authorization and signature Report Authorization This section formally concludes the Form 8-K filing, indicating that the registrant has duly authorized and signed the report - The report was signed on October 3, 2025, by Scott T. Reents, Executive Vice President and Chief Financial Officer of ABBVIE INC[14]